Quality of Life in Cancer Patients undergoing Chemotherapy

Dehkordi, Ali Hasanpour; Heydarnejad, Mohammad Saeed; Fatehi, Daryoush

doi:10.5001/omj.2009.40

Cited by 68 publications

(64 citation statements)

References 23 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, Gray et al (2011) have reported that patients with lower income have lower life quality. Contrary to the present study, a study has shown that economical status has no effect on life quality (Dehkordi et al, 2009).…”

Section: Eortc Qlq C-30 Scorescontrasting

confidence: 99%

“…A study on colorectal cancer patients has shown that female patients have lower life quality (Gray et al, 2011). Another study has shown that gender has no effect on life quality (Dehkordi et al, 2009). In the present study, we found that patients who were secondary school graduate/graduate/postgraduate experienced more functional difficulties compared to patients who were literate/elementary school graduate.…”

Section: Eortc Qlq C-30 Scorescontrasting

confidence: 43%

“…Similar studies have also demonstrated that age has no effect on life quality (Dehkordi et al, 2009). Moreover et al (2004) have shown that patients who are >60 years have higher functional difficulties, and their symptoms decrease with increasing age.…”

Section: Eortc Qlq C-30 Scoresmentioning

confidence: 85%

“…A study has shown that patients with lower educational level experience more functional difficulties, compared to patients with higher educational level (Matsushita et al, 2005). Other studies have reported that educational level has no effect on life quality (Unsal et al, 2006;Dehkordi et al, 2009). …”

Section: Eortc Qlq C-30 Scoresmentioning

confidence: 98%

“…Similar to our study, another study has shown that patients with a shorter follow-up period had better life quality (Unsal et al, 2006). On the other hand, it has been reported that disease duration has no effect on life quality (Dehkordi et al, 2009).…”

Section: Eortc Qlq C-30 Scoresmentioning

confidence: 99%

See 4 more Smart Citations

Anxiety, Depression Levels and Quality of Life in Patients with Gastrointestinal Cancer in Turkey

Bektas¹,

Demir²

2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Eortc Qlq C-30 Scorescontrasting

confidence: 99%

Section: Eortc Qlq C-30 Scorescontrasting

confidence: 43%

Section: Eortc Qlq C-30 Scoresmentioning

confidence: 85%

Section: Eortc Qlq C-30 Scoresmentioning

confidence: 98%

Section: Eortc Qlq C-30 Scoresmentioning

confidence: 99%

See 3 more Smart Citations

Anxiety, Depression Levels and Quality of Life in Patients with Gastrointestinal Cancer in Turkey

Bektas¹,

Demir²

2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Trajectories of health‐related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study

Versluis,

Raijmakers,

Baars

et al. 2023

Cancer

View full text Add to dashboard Cite

BackgroundSupport for health‐related quality of life (HRQOL) is an essential part of cancer care in the final stages of life, yet empirical guidance regarding HRQOL and symptom trajectories is lacking.AimTo assess the change in HRQOL and symptom burden in the last year of life in patients with advanced cancer and its association with health care–related factors, cancer‐specific treatment, and comorbidity.MethodsA prospective, multicenter, observational study in patients with advanced cancer (eQuiPe). Three monthly questionnaires included European Organization for Research and Treatment of Cancer Quality of Life‐C30 and reported continuity of care. Multivariable mixed‐effects analysis was used to assess the association between HRQOL and health care–related factors.ResultsA total of 762 deceased patients were included with a mean age of 66 (SD, 10) years and 52% were male. The most common primary tumors were lung (29%), colorectal (20%), and breast cancer (13%). Mean overall HRQOL decreased in the last 9 months of life, with the greatest decrease in the last 3 months (β –16.2). Fatigue, pain, appetite loss, dyspnea, constipation, and nausea worsened significantly in the last year of life. Multimorbidity (β –7.5) and a better reported continuity of care (β 0.7) were both significantly associated with the trajectory of HRQOL.ConclusionMean overall HRQOL begins to decline 9 months before death, highlighting the need for early identification and (re)assessment of different symptoms as aspects of HRQOL follow different trajectories. Multimorbidity and reported continuity of care may be associated with the trajectory of HRQOL.

show abstract

Chemotherapy‐induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia

Hain

Wilcox

et al. 2019

JCSM Rapid Communications

View full text Add to dashboard Cite

Background Chemotherapy used to treat malignancy can lead to loss of skeletal muscle mass and reduced force production, and can reduce bone volume in mice. We have shown that bone-muscle crosstalk is a key nexus in skeletal muscle function and bone homeostasis in osteolytic breast cancer bone metastases. Because chemotherapy has significant negative side effects on bone mass, and because bone loss can drive skeletal muscle weakness, we have examined the effects of chemotherapy on the musculoskeletal system in mice with breast cancer bone metastases. Methods and results Six-week-old Female athymic nude mice were inoculated with 10 5 MDA-MB231 human breast cancer cells into the left ventricle and bone metastases were confirmed by X-ray. Mice were injected with carboplatin at a dose of 60mg/kg once per week starting 4 days after tumor inoculation. Skeletal muscle was collected for biochemical analysis and extensor digitorum longus (EDL) whole muscle contractility was measured. The femur and tibia bone parameters were assessed by microCT and tumor burden in bone was determined by histology. Healthy mice treated with carboplatin lose whole body weight and have reduced individual muscle weights (gastrocnemius, tibialis anterior (TA), and EDL), reduced trabecular bone volume (BV/TV), and reduced EDL function. Mice with MDA-MB-231 bone metastases treated with carboplatin lose body weight, and have reduced EDL function as healthy mice treated with carboplatin. Mice with MDA-MB-231 bone metastases plus carboplatin do have reduced proximal tibia BV/TV compared to carboplatin alone, but carboplatin does reduce tumor burden in bone. Conclusions Our data shows that carboplatin treatment, aimed at reducing tumor burden, contributes to cachexia and trabecular bone loss. The muscle atrophy and weakness may occur through bone-muscle crosstalk and would lead to a feed-forward cycle of musculoskeletal degradation. Despite anti-tumor effects of chemotherapy, musculoskeletal impairment is still significant in mice with bone metastases.

show abstract

Quality of Life in Cancer Patients undergoing Chemotherapy

Abstract: This study suggests that encouraging cancer patients to complete a CT course plays an important role in the treatment outcome and the QoL in cancer patients undergoing CT.

Cited by 68 publications

References 23 publications

Anxiety, Depression Levels and Quality of Life in Patients with Gastrointestinal Cancer in Turkey

Anxiety, Depression Levels and Quality of Life in Patients with Gastrointestinal Cancer in Turkey

Trajectories of health‐related quality of life and symptom burden in patients with advanced cancer towards the end of life: Longitudinal results from the eQuiPe study

Chemotherapy‐induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia

Contact Info

Product

Resources

About